**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Valmiki Maharaj
University of Minnesota
Department of Medicine
Division of Cardiovascular Disease
Section Advanced Heart Failure and Transplant Cardiology
Minneapolis, MN 55455
maha0104@umn.edu
612-281-7440

**Main Body of the Abstract**
Cardiac amyloidosis is becoming increasingly recognized.  Due to advances in imaging, namely Technetium Pyrophosphate Scintigraphy (PYP scan), the diagnostic algorithm has been simplified where biopsy of affected tissue is rarely needed.  Early screening and appropriate treatment is pivotal to improve patient outcomes.  However, screening of cardiac amyloid with a PYP scan is still quite low despite its recognized prevalence.  We determined to look at which providers consider screening their patients with PYP imaging.
This was a single center retrospective data analysis looking at all the PYP scans ordered at the University of Minnesota and M Health Fairview from May 2019 (when the scan first became available for use) to December 31 2023.
390 scans were performed overall, though only 254 were for clinical use, as 136 were for research purposes only.  Of the 254 scans, a cardiology provider ordered 250 scans.  Of the 4 scans ordered by non cardiologists, 2 were from hematology and oncology, and two from hospitalist medicine.
Of the 250 scans ordered by cardiology providers, 102 were ordered by heart failure trained cardiologists, 87 by general cardiologists, 11 by interventional cardiologists, and 2 by electrophysiologists.  Mid Level advanced practice providers and trainees, within the cardiology division, ordered 42 and 7 scans respectively.
Education of amyloidosis to other specialties outside of cardiology, such as primary care, internal medicine, neurology, with empowerment to perform an evaluation for cardiac amyloidosis, is needed if the disease is going to be diagnosed at earlier stages.



Technetium Pyrophosphate Scintigraphy Ordering Provider Specialties PB138 (#527)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.